Opus Genetics, Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $14.2M | $11.0M | $19.0M | $39.9M | $589,000 |
| Research and development | $30.8M | $26.9M | $17.7M | $14.4M | $15.2M |
| Operating expenses | $52.8M | $73.1M | $29.6M | $21.6M | $23.3M |
| Operating income | -$38.6M | -$62.1M | -$10.6M | $18.2M | -$22.7M |
| Interest expense | $129,000 | $0 | $0 | $9,000 | $2,000 |
| Pretax income | -$49.6M | -$57.5M | -$10.0M | $18.2M | -$56.7M |
| Income tax expense | $0 | $0 | $12,000 | $315,000 | $0 |
| Net income | -$49.6M | -$57.5M | -$10.0M | $17.9M | -$56.7M |
| Balance Sheet | |||||
| Cash and equivalents | $45.1M | $30.3M | $50.5M | $42.6M | $24.5M |
| Current assets | $50.0M | $36.6M | $53.9M | $49.0M | $26.1M |
| Total assets | $50.2M | $36.9M | $53.9M | $49.0M | $26.1M |
| Current liabilities | $7.8M | $11.3M | $4.0M | $2.8M | $3.9M |
| Total liabilities | $34.9M | $11.3M | $4.0M | $2.8M | $3.9M |
| Stockholders' equity | $15.3M | $6.7M | $49.9M | $46.2M | $22.2M |
| Cash Flow Statement | |||||
| Cash from operations | -$35.3M | -$25.6M | -$1.1M | $14.3M | -$19.4M |
| Depreciation and amortization | $53,000 | $10,000 | $6,000 | $4,000 | $4,000 |
| Stock-based compensation | $3.4M | $3.4M | $3.5M | $1.8M | $1.9M |
Shares outstanding 81.4M · Free float 58.8%
Annual filing data through FY ended December 31, 2025; float as of July 12, 2026.